Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
-
December 9, 2023
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
-
November 30, 2023
EISAI’S SALES SUBSIDIARY COLLABORATES WITH MINISTRY OF PUBLIC HEALTH (MOPH) IN THAILAND
-
November 22, 2023
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 77TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING
-
November 20, 2023
LEQEMBI® Wins Best New Drug And Clinical Advance Of The Year at The Scrip Awards 2023
-
November 16, 2023
EISAI NAMED AS “GREATEST IR IMPROVEMENT PREMIUM COMPANY” AND “BEST CONTINUAL IR EFFORTS PREMIUM COMPANY” AT THE JAPAN INVESTOR RELATIONS ASSOCIATION 30TH ANNIVERSARY COMMEMORATIVE AWARDS
-
October 26, 2023
EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER’S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
INVESTIGATIONAL SUBCUTANEOUS FORMULATION CLEARS 14% MORE PLAQUE THAN IV, PHARMACOKINETICS (AUC) 11% HIGHER, AND SIMILAR ARIA RATES TO IV
76% OF PATIENTS SHOWED NO DECLINE AND 60% SHOWED CLINICAL IMPROVEMENT AT 18 MONTHS IN LOW-TAU SUBPOPULATION IN ADDITIONAL ANALYSIS OF CLARITY AD
DUAL-ACTING LEQEMBI SUPPORTS BRAIN NEURON FUNCTION BY REMOVING HIGHLY TOXIC PROTEINS (PROTOFIBRILS) THAT CAN CONTINUE TO CAUSE NEURONAL INJURY AND DEATH EVEN AFTER PLAQUE REMOVAL, OFFERING EARLY AD PATIENTS THE OPPORTUNITY FOR CONTINUED BENEFIT
-
October 25, 2023
LEQEMBI® (LECANEMAB-IRMB) NAMED ONE OF TIME’S BEST INVENTIONS OF 2023
-
October 16, 2023
EISAI TO PRESENT NEW DATA FROM LEQEMBI® (LECANEMAB-IRMB) PHASE 3 CLARITY AD STUDY AND OTHER ALZHEIMER’S DISEASE PIPELINE RESEARCH AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
Update on LEQEMBI Investigational Subcutaneous Formulation
-
October 11, 2023
EISAI TO PRESENT RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO CONGRESS 2023
-
October 4, 2023
Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.
-
September 28, 2023
EISAI LAUNCHES NEW “INNOVATION” PAGE ON CORPORATE WEBSITE
-
September 28, 2023
TOKIO MARINE NICHIDO AND EISAI
CO-DEVELP INDUSTRY’S FIRST “DEMENTIA CARE SUPPORT INSURANCE”
-
September 25, 2023
“LEQEMBI® Intravenous Infusion” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
-
September 22, 2023
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Two Phase 3 Trials Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
-
September 21, 2023
RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMER’S DAY, SEPTEMBER 21
LIFE GOES ON 2023: TWO MEMORIES, ONE STORY
LEARNING HELPS US TO BE KIND
-
September 12, 2023
EISAI ESTABLISHES THEORIA TECHNOLOGIES CO., LTD., A NEW DIGITAL BUSINESS COMPANY TO BUILD A DEMENTIA ECOSYSTEM
-
August 25, 2023
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-010 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
-
August 4, 2023
EISAI LISTED FOR 22ND CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
-
August 1, 2023
ORGANIZATIONAL REFORM AND CHANGES OF CORPORATE OFFICERS
-
July 20, 2023
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer’s disease
New data on subcutaneous formulation shows promising PK /PD data modeling on efficacy and safety, representing a potential new option for administering therapy
-
July 12, 2023
EISAI TO PRESENT THE LATEST ALZHEIMER’S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023
-
July 11, 2023
CHANGES OF CORPORATE OFFICERS
-
July 7, 2023
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease
The Centers for Medicare & Medicaid Services (CMS) announced broader Medicare coverage of LEQEMBI
-
June 30, 2023
EISAI TRANSFERS ALL FUTURE ECONOMIC RIGHTS FOR ELACESTRANT, A SELECTIVE ESTROGEN RECEPTOR DEGRADER, TO DRI HEALTHCARE
-
June 29, 2023
Position and Policy Regarding Reduction of the Investment Unit of the Company's Shares
-
June 29, 2023
NEW NEURII RESEARCH COLLABORATION BETWEEN EISAI, GATES VENTURES, HEALTH DATA RESEARCH UK, LIFEARC AND THE UNIVERSITY OF EDINBURGH TO DEVELOP DIGITAL SOLUTIONS FOR DEMENTIA IS ANNOUNCED
-
June 22, 2023
EISAI’S “NOUKNOW®” WILL CONTINUE TO BE UTILIZED FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2023 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY
ACHIEVEMENT OF OUTCOME INDICATORS IN FY2022 PAY FOR SUCCESS CONTRACT
-
June 10, 2023
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease
The PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with designation of priority review
LEQEMBI received accelerated approval from the FDA for the treatment of early Alzheimer’s disease on January 6, 2023
-
June 8, 2023
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE IN SOUTH KOREA
-
June 6, 2023
Notification of Ransomware Incident
-
June 2, 2023
EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 37TH ANNUAL SLEEP 2023 MEETING
-
May 26, 2023
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
After four years of follow-up, LENVIMA plus KEYTRUDA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial
Final results will be presented at ASCO 2023 in an oral abstract session
-
May 25, 2023
EISAI’S INITIATIVES FOR DEVELOPING NEW MEDICINES FOR NEGLECTED TROPICAL DISEASES AND MALARIA AND COMMITMENT FOR FUNDING TO THE 3RD PHASE OF GLOBAL HEALTH INNOVATIVE TECHNOLOGY FUND ACTIVITIES
-
May 24, 2023
EISAI DELIVERS NEW DATA AND HIGHLIGHTS CONTINUED PROGRESS OF ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023
-
May 22, 2023
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE IN GREAT BRITAIN
-
May 17, 2023
EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB IN JAPAN USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
-
May 16, 2023
HEALTH CANADA ACCEPTS NEW DRUG SUBMISSION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE
-
May 15, 2023
Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Revision of the Stock Compensation System (Officers’ Compensation BIP Trust)
-
May 15, 2023
Notification Regarding the Revision of the Compensation System for Directors and Corporate Officers and Stock Compensation System (Officers’ Compensation BIP Trust) and Additional Contribution
-
May 9, 2023
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2023
-
May 8, 2023
EISAI ENTERS INTO JOINT DEVELOPMENT AGREEMENT WITH BLISSBIO FOR ANTIBODY DRUG CONJUGATE BB-1701 WITH OPTION RIGHTS FOR STRATEGIC COLLABORATION
-
April 7, 2023
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 Trials of LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)
-
April 6, 2023
EISAI COMPLETES A MAJOR RENOVATION OF TSUKUBA RESEARCH LABORATORIES
AS A GLOBAL DRUG DISCOVERY CENTER AIMING FOR CONNECTING HUMAN AND HUMAN, AND DATA, AND THE WORLD
-
April 4, 2023
EISAI PUBLISHES LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
Treatment with Lecanemab Resulted in a Delay of 2 to 3 Years in the Mean Time to Progression to More Severe Stages of Alzheimer’s Disease, Compared with Standard of Care Alone
Subgroup Analysis Suggested that Earlier Initiation of Treatment with Lecanemab May Have a Greater Impact on Disease Progression
-
April 3, 2023
EISAI ENTERS INTO AGREEMENT WITH NATIONAL CANCER CENTER TO COLLABORATE ON INVESTIGATOR-INITIATED CLINICAL RESEARCH FOR ANTICANCER AGENT TAZEMETOSTAT BASED ON “PATIENT-PROPOSED HEALTHCARE SERVICES” SYSTEM
-
March 31, 2023
EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING
-
March 31, 2023
ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS
-
March 24, 2023
EISAI TO PRESENT RESEARCH FROM ONCOLOGY PORTFOLIO AT THE SOCIETY OF GYNECOLOGIC ONCOLOGY (SGO) 2023 ANNUAL MEETING ON WOMEN’S CANCER
-
March 23, 2023
EISAI TO PRESENT NEW LECANEMAB DATA, INCLUDING RESEARCH EVALUATING SAFETY PROFILE, CLINICAL OUTCOMES AND QUALITY OF LIFE MEASURES, AS WELL AS OTHER IMPORTANT ALZHEIMER’S DISEASE RESEARCH, AT THE AD/PD™ 2023 ANNUAL MEETING
Presentations Explore ARIA with the Use of Antiplatelets or Anticoagulants and Isolated ARIA-H in Patients from Eisai’s Lecanemab Phase 3 Confirmatory Clarity AD Study in Early Alzheimer’s Disease
-
March 20, 2023
EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
-
March 14, 2023
U.S. VETERANS’ HEALTH ADMINISTRATION (VHA) PROVIDES COVERAGE OF LEQEMBI™ (LECANEMAB-IRMB) TWO MONTHS AFTER LEQEMBI’S FDA ACCELERATED APPROVAL FOR VETERANS LIVING WITH EARLY STAGES OF ALZHEIMER’S DISEASE
EISAI IS PROUD TO SUPPORT U.S. VETERANS LIVING WITH EARLY STAGES OF ALZHEIMER’S DISEASE AND WILL CONTINUE TO TRANSPARENTLY SHARE OUR HIGH-QUALITY DATA WITH THE VHA
-
March 10, 2023
EISAI RECEIVES THE “BASIC ACHIEVEMENT GRAND PRIZE” AT THE 2023 J-WIN DIVERSITY AWARD
-
March 9, 2023
EISAI CERTIFIED AS A 2023 HEALTH AND PRODUCTIVITY MANAGEMENT OUTSTANDING ORGANIZATION (WHITE 500)
-
March 6, 2023
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval
Priority Review accelerates FDA review time with a Prescription Drug User Fee Act (PDUFA) target action on July 6, 2023
-
March 2, 2023
BIOGEN JAPAN AND EISAI PROVIDE UPDATE ON CO-PROMOTION OF MULTIPLE SCLEROSIS TREATMENTS IN JAPAN
-
February 28, 2023
BIOLOGICS LICENSE APPLICATION FOR LECANEMAB DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION
-
February 20, 2023
DISSOLUTION OF BRACCO-EISAI JOINT VENTURE
-
January 30, 2023
LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN
-
January 27, 2023
MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY
-
January 19, 2023
EISAI COMMENCES BUSINESS ACTIVITIES AT NEW PHARMA SALES SUBSIDIARY IN ISRAEL
-
January 18, 2023
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 18, 2023
EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023
Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal Cancer
Research from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Unresectable Hepatocellular Carcinoma
-
January 16, 2023
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN JAPAN
-
January 13, 2023
EISAI LAUNCHES RENEWED SUSTAINABILITY PAGE
-
January 11, 2023
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE IN EUROPE
-
January 7, 2023
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Submission for traditional approval follows FDA accelerated approval of LEQEMBI on the same day, and is based on data from the confirmatory Phase 3 Clarity AD clinical trial
-
January 7, 2023
Eisai’s Commitment to Scientific Evidence and Patient Safety
-
January 7, 2023
EISAI’S APPROACH TO U.S. PRICING FOR LEQEMBI™ (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER’S DISEASE, SETS FORTH OUR CONCEPT OF “SOCIETAL VALUE OF MEDICINE” IN RELATION TO “PRICE OF MEDICINE”
MAXIMIZING VALUE FOR ALL STAKEHOLDERS WHILE GIVING BACK VALUE TO SOCIETY
-
January 7, 2023
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer’s Disease
Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™
Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials
-
December 28, 2022
YASUDA LOGISTICS AND EISAI ENTERS AGREEMENT TO TRANSFER EISAI’S SUBSIDIARY EISAI DISTRIBUTION TO YASUDA LOGISTICS
-
December 23, 2022
ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER
-
December 23, 2022
EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA
-
December 22, 2022
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
-
December 20, 2022
EISAI TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA® (perampanel) CIII IN UNITED STATES TO CATALYST PHARMACEUTICALS
-
December 16, 2022
EISAI TERMINATES SPONSORED AMERICAN DEPOSITARY RECEIPT PROGRAM
-
December 15, 2022
EISAI AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ENTER INTO COMPREHENSIVE RESEARCH COLLABORATION AGREEMENT AIMING TO CREATE NEW THERAPIES FOR NEURODEGENERATIVE DISEASES
-
December 1, 2022
EISAI TO PRESENT PRECLINICAL AND CLINICAL RESEARCH ON ERIBULIN AT THE 2022 SAN ANTONIO BREAST CANCER SYMPOSIUM
-
November 30, 2022
EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER’S DISEASE AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
-
November 30, 2022
ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER’S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE
-
November 29, 2022
(REVISION) ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER
-
November 29, 2022
EISAI ANNOUNCES APPROVAL OF PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT® FOR TREATMENT OF DEMENTIA WITH LEWY BODIES
-
November 24, 2022
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING
-
November 22, 2022
To Develop Japan’s First Blood Biomarker-Based Diagnostic Workflow for Dementia
Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
-
November 21, 2022
EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMER’S DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
-
November 16, 2022
METOJECT® SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) LAUNCHED IN JAPAN FOR RHEUMATOID ARTHRITIS
-
November 7, 2022
EISAI TO DIVEST RIGHTS FOR MUSCLE RELAXANT MYONAL® AND VERTIGO AND EQUILIBRIUM DISTURBANCE TREATMENT MERISLON® IN ASIA TO DKSH
-
November 4, 2022
EISAI'S SALES SUBSIDIARY COLLABORATES WITH THAI LIFE INSURANCE TO SUPPORT ACCESS TO TREATMENTS FOR DEMENTIA, INCLUDING ALZHEIMER’S DISEASE, IN THAILAND
-
November 2, 2022
EISAI SATISFIES ALL-CASE STUDY REQUIREMENT FOR ANTIEPILEPTIC AGENT INOVELON®
-
October 31, 2022
EISAI ANNOUNCES PLANS TO SUBMIT APPLICATION FOR PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT® FOR TREATMENT OF DEMENTIA WITH LEWY BODIES BASED ON RESULTS OF DRUG REEXAMINATION
-
October 4, 2022
EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN
TO STRENGTHEN ITS RESEARCH AND DEVELOPMENT FUNCTION FOR INJECTABLE DRUG FORMULATIONS
-
September 28, 2022
LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE
-
September 26, 2022
Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange
(Purchase of Treasury Shares under Article 234, Paragraphs 4 and 5 and Article 416, Paragraph 4 of the Companies Act)
-
September 26, 2022
METOJECT® SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS
-
September 21, 2022
RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMER’S DAY, SEPTEMBER 21
“LEARNING HELPS US TO BE KIND” LIFE GOES ON: NO WAY ITS NOT HERE / TIMESLIP
-
September 12, 2022
Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
-
September 12, 2022
Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN®) at the European Society for Medical Oncology (ESMO) Congress 2022
Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Clinical Studies
-
September 6, 2022
Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Demonstrate the Clinical Benefit of Lenvatinib plus Pembrolizumab and the Combination’s Potential Across Difficult-to-Treat Cancers
Post-Hoc Analysis of Three Pivotal Phase 3 Studies on Eribulin’s Efficacy in Newly-Defined HER2-low Metastatic Breast Cancer Showcases Eisai’s Commitment to Advancing Understanding of Our Medicines
-
August 30, 2022
SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR ANTIEPILEPTIC DRUG FYCOMPA® INJECTION FORMULATION AS A NEW ROUTE OF ADMINISTRATION
-
August 24, 2022
EISAI INC. COLLABORATES WITH C2N TO BUILD AWARENESS AND REAL-WORLD EVIDENCE FOR BLOOD-BASED ASSAYS IN THE DIAGNOSIS OF PEOPLE LIVING WITH COGNITIVE IMPAIRMENT IN CLINICAL PRACTICE IN THE U.S. OUTSIDE OF CLINICAL TRIAL SETTINGS
-
August 12, 2022
HONDA, EISAI, OITA UNIVERSITY AND USUKI CITY MEDICAL ASSOCIATION ENTER INTO JOINT RESEARCH AGREEMENT TO VERIFY THE RELATIONSHIP BETWEEN COGNITIVE FUNCTION, DAILY PHYSICAL CHANGES, AND DRIVING ABILITY, WITH THE AIM OF REALIZING A SOCIETY IN WHICH ELDERLY DRIVERS CAN MAINTAIN THEIR SAFETY AND HEALTH
-
August 9, 2022
EISAI AND LIFENET ENTER INTO CAPITAL AND BUSINESS ALLIANCE AGREEMENT AIMED AT BUILDING ECOSYSTEM TO REDUCE BURDEN OF MEDICAL AND NURSING CARE
-
August 4, 2022
EISAI PRESENTS NEW FINDINGS ON LECANEMAB’S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022
-
August 3, 2022
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
-
July 26, 2022
EISAI LISTED FOR 21ST CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
-
July 26, 2022
EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMER’S DISEASE RESEARCH AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022
-
July 25, 2022
AΒ-RELATED PAPER PUBLISHED IN THE AMERICAN SCIENTIFIC JOURNAL SCIENCE
-
July 15, 2022
REFORM OF GLOBAL RESEARCH AND DEVELOPMENT ORGANIZATION AND CHANGES OF CORPORATE OFFICERS <effective as of July 15, 2022>
-
July 6, 2022
THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI’S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
-
June 29, 2022
Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
-
June 28, 2022
E.DESIGN INSURANCE AND EISAI ENTER INTO BUSINESS ALLIANCE AIMING TO PROMOTE SAFE DRIVING AND EXTEND DRIVING LIFE IN AN AGING SOCIETY UNDER THE THEME OF “IMPROVING BRAIN HEALTH (BRAIN PERFORMANCE) FOR SAFE DRIVING”
-
June 24, 2022
EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP “KIGALI DECLARATION” FOR ELIMINATING NEGLECTED TROPICAL DISEASES
CEO NAITO APPOINTED AS ONE OF 100 GLOBAL LEADERS COMMITTED TO ELIMINATING NEGLECTED TROPICAL DISEASES
-
June 22, 2022
EISAI’S “NOUKNOW®”, DIGITAL TOOL FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE, IS TO UTILIZE FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2022 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY
-
June 22, 2022
EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
Second Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling
-
June 8, 2022
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2023
-
June 6, 2022
EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETING
Poster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202) in Solid Tumors (Abstract: #5513)
Poster Presentation Features Analyses Based on PK/PD Modeling/Simulations for Dose Optimization of Farletuzumab Ecteribulin Including Findings for Body Surface Area-Based Dosing (Abstract: #3090)
-
June 3, 2022
EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING
-
May 30, 2022
Announcement of a Summary Share Exchange (kan’i kabushiki kokan) to Make Sunplanet Co., Ltd. a Wholly Owned Subsidiary
-
May 27, 2022
EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022
Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisai’s Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for Patients
Presentations Featuring Post-Hoc Analyses from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Advanced Renal Cell Carcinoma and Advanced Endometrial Carcinoma
-
May 27, 2022
MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS ORPHAN DRUG DESIGNATION IN JAPAN TO MECOBALAMIN ULTRAHIGH-DOSE FORMULATION WITH PROSPECTIVE INDICATION FOR DELAYING THE PROGRESSION OF DISEASE AND FUNCTIONAL IMPAIRMENT OF AMYOTROPHIC LATERAL SCLEROSIS
-
May 20, 2022
“MOVICOL® HD” Launched
A New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan
-
May 13, 2022
Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Continuation of the Performance-Related Stock-Based Compensation System
-
May 13, 2022
Notification Regarding the Continuation of the Performance-Related Stock-Based Compensation System
-
May 13, 2022
Notification Regarding Partial Amendment to the Articles of Incorporation
-
May 13, 2022
CHANGES OF CORPORATE OFFICERS
-
May 10, 2022
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
-
May 10, 2022
EISAI INITIATES PREPARATION FOR NEW DRUG APPLICATION, BASED ON THE RESULTS OF AN INVESTIGATOR-INITIATED CLINICAL TRIAL OF ULTRAHIGH-DOSE MECOBALAMIN FOR AMYOTROPHIC LATERAL SCLEROSIS IN JAPAN
-
May 3, 2022
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2022
-
April 27, 2022
Discontinuance (abolition) of the Policy for Protection of the Company’s Corporate Value and Common Interests of Shareholders
-
April 27, 2022
LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF INVESTIGATIONAL LECANEMAB IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE PUBLISHED IN A PEER-REVIEWED JOURNAL, NEUROLOGY AND THERAPY
-
April 8, 2022
EISAI STATEMENT ON THE CENTERS FOR MEDICARE AND MEDICAID SERVICES’ NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMER’S DISEASE
-
April 1, 2022
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
-
March 28, 2022
Announcement about an approval for additional indication of Jyseleca®, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapies
Approval of additional indication based on Phase IIb/III SELECTION data for patients with active moderate-to-severe ulcerative colitis
-
March 22, 2022
Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimer’s Disease
The Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PDTM 2022)
-
March 22, 2022
LATEST FINDINGS ON LECANEMAB – CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS – PRESENTED AT AD/PD™ 2022 ANNUAL MEETING
-
March 15, 2022
ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMER‘S DISEASE TREATMENT COLLABORATION AGREEMENT WITH BIOGEN
-
March 15, 2022
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
-
March 11, 2022
EISAI TO PRESENT NEW LECANEMAB DATA EXPLORING DISTINCT MECHANISM OF ACTION AND CLINICAL OUTCOMES, DISEASE STATE (DSE) SYMPOSIUM, AND OTHER PIPELINE ASSETS AT THE AD/PD™ 2022 ANNUAL MEETING
-
March 9, 2022
EISAI CERTIFIED AS THE 2022 HEALTH AND PRODUCTIVITY MANAGEMENT OUTSTANDING ORGANIZATION (WHITE 500)
-
March 7, 2022
LENVIMA®（LENVATINIB）IN COMBINATION WITH KEYTRUDA®（PEMBROLIZUMAB）APPROVED IN TAIWAN FOR THE TREATMENT OF PATIENTS WITH ADVANCED ENDOMETRIAL CARCINOMA WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY IN ANY SETTING AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
-
March 4, 2022
EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB
-
February 25, 2022
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
Results From CLEAR/KEYNOTE-581 Showed LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Disease Progression or Death by 61%, With a Median Progression-Free Survival of Nearly Two Years Versus Nine Months for Sunitinib
LENVIMA Plus KEYTRUDA Now Approved in Japan for Two Types of Cancer
-
February 10, 2022
EISAI SUBMITS FORMAL COMMENTS TO THE CENTERS FOR MEDICARE AND MEDICAID SERVICES’ PROPOSED NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMER’S DISEASE
-
February 1, 2022
EISAI RECEIVES THE TOKYO GOVERNOR PRIZE FOR CORPORATE GOVERNANCE OF THE YEAR® 2021
-
January 31, 2022
LENVIMA®（LENVATINIB）IN COMBINATION WITH KEYTRUDA®（PEMBROLIZUMAB）APPROVED IN TAIWAN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
-
January 28, 2022
EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES
10 YEAR ANNIVERSARY EVENT OF THE PUBLIC-PRIVATE PARTNERSHIP “LONDON DECLARATION”
-
January 28, 2022
Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
-
January 20, 2022
Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
-
January 19, 2022
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 19, 2022
FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI’S ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU
EISAI’S ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB SELECTED AS THE BACKGROUND THERAPY FOR THE TAU NEXGEN STUDY
-
January 17, 2022
EISAI TO PRESENT ABSTRACTS ON LENVATINIB AT 2022 ASCO GASTROINTESTINAL CANCERS SYMPOSIUM
-
January 13, 2022
Eisai’s Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
-
January 13, 2022
EISAI TO LAUNCH DIGITAL TOOL “CogMate™” IN TAIWAN AND HONG KONG FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH)
-
January 6, 2022
EISAI ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH ROIVANT CONCERNING INVESTIGATIONAL ANTICANCER AGENT H3B-8800,A SPLICING MODULATOR
